Natera (NTRA) is down roughly 3% on Thursday, April 16, 2026, in a continuation of a recent pullback that has repeatedly tested the $200 level. With no single company press release driving the move today, the slide looks driven by sentiment and positioning: valuation sensitivity after a strong run, heightened attention to insider-selling disclosures, and investors re-weighting near-term profitability expectations versus long-term growth.

Recent Form 4 activity has kept insider sales in focus, including sales disclosed for early April. That type of headline can pressure momentum-driven names, especially after a large-cap biotech/diagnostics stock has rallied and investors look for reasons to de-risk into liquidity events.

Natera’s most recent reported quarter highlighted rapid growth and improving margins, with Q4 2025 revenue of $665.5 million and full-year 2025 revenue of $2.306 billion. The company also guided to 2026 revenue of $2.62 billion to $2.70 billion with gross margin of about 63% to 65%, but the stock’s premium valuation leaves little room for disappointment, making it more vulnerable to routine profit-taking.

Traders are watching whether NTRA can reclaim and hold the $200 level, since repeated breaks below that area can accelerate technical selling. Near-term catalysts that could shift the tape include additional insider filings, incremental analyst note activity, and any updates around reimbursement, litigation overhangs, or oncology demand indicators tied to Signatera volumes.